Windlas Biotech Ltd. News and Updates

Name: Latest research reports of Windlas Biotech Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Windlas Biotech Ltd.
Rating: 3
Author: Prabhudas Lilladhar

Keep track of all breaking news on Windlas Biotech Ltd. from all sources in a single place.

Load latest

Windlas Biotech Ltd.

13 May 2022

956.65

-2.73%

Earnings Call for Q4FY22 of Windlas Biotech

Conference Call with Windlas Biotech Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.

Windlas Biotech Ltd.

10 Feb 2022

956.65

-2.73%

Hot Stocks | Here's why you should bet on Windlas Biotech, IndusInd Bank for short term

Moneycontrol

A bullish pole flag pattern on the weekly time frame seems to have completed its throwback near 61.80 percent Fibonacci retracement and the uptrend is most likely to stretch the prices further higher.

Windlas Biotech Ltd. is trading above its 200 day SMA of 946.5

Windlas Biotech Ltd.

23 Dec 2021

956.65

-2.73%

India's API push to fructify in three to five years, says MD at Windlas Biotech

Business Line

Experts say focus on price and not on Chinese dependence impacting India

Windlas Biotech Ltd. is trading below its 30 day SMA of 996.1

Windlas Biotech Ltd.

01 Nov 2021

956.65

-2.73%

Earnings Call for Q2FY22 of Windlas Biotech

Conference Call with Windlas Biotech Ltd. Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Windlas Biotech Ltd.

18 Aug 2021

956.65

-2.73%

Windlas Biotech hits new low since listing; falls 16% against issue price

Business Standard

The stock was trading lower for the third straight day since listing

Windlas Biotech Ltd. has gained 24.42% in the last 3 Months

Windlas Biotech Ltd.

16 Aug 2021, 05:51PM

956.65

-2.73%

Windlas Biotech shares settle with 11.6% loss to issue price in debut trade

Moneycontrol

Cumulatively, Windlas Biotech traded with volume of 44.3 lakh equity shares on the BSE and NSE.

Windlas Biotech Ltd. is trading above its 200 day SMA of 946.5

Windlas Biotech listing disappoints, Exxaro Tiles jumps 10%: What should investors do now?

Moneycontrol | 16 Aug 2021, 04:13PM 4 more

Windlas Biotech Ltd.

06 Aug 2021

956.65

-2.73%

Windlas Biotech IPO oversubscribed 22.46 times on closing day

Business Standard

The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription. The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data. The category for Qualified Institutional Buyers(QIBs) was subscribed 24.40 times, non-institutional investors 15.73 times, and retail individual investors(RIIs) 24.27 times. The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares. The Rs 401.53-crore offer had a price range of Rs 448-460 per share. Windlas Biotech on Tuesday raised over Rs 120 crore from anchor investors. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capi

Windlas Biotech Ltd.'s price crossed below 50Day SMA today

Windlas Biotech IPO oversubscribed by 8.48 times, QIB portion booked just 13% on final day

Moneycontrol | 06 Aug 2021

Windlas Biotech Ltd.

05 Aug 2021

956.65

-2.73%

Subscribe to Windlas Biotech: Prabhudas Lilladher

Moneycontrol

Prabhudas Lilladher has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 05, 2021.

Windlas Biotech Ltd. is trading above its 200 day SMA of 946.5

Subscribe to Windlas Biotech: Hem Securities

Moneycontrol | 05 Aug 2021

Windlas Biotech Ltd.

05 Aug 2021

956.65

-2.73%

IPO Note - Direct play on CMO offers alternative opportunity for investors - SUBSCRIBE

IPO Note: Windlas Biotech Ltd.

Prabhudas Lilladhar

experience in manufacturing (solid/ liquid) multiple dosage offers a comprehensive range of CDMO services in India. Over time Windlas evolved and 6) strong financial performance with experienced management. It owns...

Windlas Biotech Ltd. is trading above its 200 day SMA of 946.5

Windlas Biotech Ltd.

04 Aug 2021

956.65

-2.73%

Windlas Biotech offers its shares at 64x PE. Should you subscribe?

Economic Times

The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS).

Windlas Biotech Ltd. has gained 24.42% in the last 3 Months

Subscribe to Windlas Biotech: Choice Equity Broking

Moneycontrol | 03 Aug 2021 1 more

VOTE: Is Windlas Biotech Ltd. worth buying?

64 Votes:

Buy 84.38%

Sell 12.5%

Hold 3.12%

79.15% Gain from 52W Low

Windlas Biotech Ltd. News and Updates

Keep track of all breaking news on Windlas Biotech Ltd. from all sources in a single place.